Form 4: Organogenesis Holdings Director Leibowitz Receives Stock Grant

Director Arthur S. Leibowitz of Organogenesis Holdings Inc. reports the acquisition of restricted stock units (RSUs) under the company's 2018 Equity Incentive Plan.

Summary

• Arthur S. Leibowitz, a director at Organogenesis Holdings Inc., filed a Form 4 to report changes in beneficial ownership.
• On February 19, 2025, Leibowitz acquired 49,575 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• These RSUs were granted under the Organogenesis 2018 Equity Incentive Plan.
• Each RSU represents the right to receive one share of Organogenesis Class A common stock upon vesting.
• The RSUs vest in full on February 15, 2026.
• Following the transaction, Leibowitz directly owns 237,186 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of RSUs is a standard practice and suggests confidence in the company's future performance. It's a routine transaction, but it does align director interests with shareholders.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting date of the RSUs.

Industry Context

Stock grants to directors are a common practice in publicly traded companies to incentivize performance and align interests with shareholders. The specifics of the grant, such as vesting schedule and number of shares, are tailored to the individual and the company's compensation policies.

Stakeholder Impact

• The RSU grant aligns the director's interests with those of the shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates

Keywords

Organogenesis Holdings Inc., Director, Form 4, RSUs, Stock Grant, Beneficial Ownership, ORGO, Equity Incentive Plan